| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 10.0 | 19.1 |
| Net income | -5.9 | -16.3 |
| EPS (diluted, $ a share) | $-0.30 | $-1.58 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -47.6% |
|---|---|
| Operating margin | -117.7% |
10-Q filed with the SEC, NASDAQ: XLO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Xilio Therapeutics, Inc.: key numbers
- Share price
- $7.70Close, Nov 16
- Market cap
- $54.4M
- Shares outstanding
- 7.06MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Xilio Therapeutics, Inc.
All →Xilio Therapeutics Financial Results
Xilio Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting the dosing of the first patient in its Phase 1/2 trial for XTX501. The company ended the quarter with $45.1 million in cash and cash equivalents, which it expects will fund operations into the second quarter of 2027.
- Term
- Q3 2026
“In the third quarter, we initiated our Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific that we believe has the potential to become a foundational backbone immunotherapy regimen for solid tumors.”
René Russo, Pharm.D., president and chief executive officer of Xilio